ATE539170T1 - Abschätzung und verringerung des risikos von graft-versus-host-reaktion - Google Patents

Abschätzung und verringerung des risikos von graft-versus-host-reaktion

Info

Publication number
ATE539170T1
ATE539170T1 AT07719640T AT07719640T ATE539170T1 AT E539170 T1 ATE539170 T1 AT E539170T1 AT 07719640 T AT07719640 T AT 07719640T AT 07719640 T AT07719640 T AT 07719640T AT E539170 T1 ATE539170 T1 AT E539170T1
Authority
AT
Austria
Prior art keywords
assessing
versus host
graft versus
risk
reducing
Prior art date
Application number
AT07719640T
Other languages
English (en)
Inventor
Claude Perreault
Chantal Baron
Roland Somogyi
Larry Greller
Original Assignee
Univ Montreal
Biosystemix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Biosystemix Ltd filed Critical Univ Montreal
Application granted granted Critical
Publication of ATE539170T1 publication Critical patent/ATE539170T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07719640T 2006-04-27 2007-04-27 Abschätzung und verringerung des risikos von graft-versus-host-reaktion ATE539170T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74576106P 2006-04-27 2006-04-27
PCT/CA2007/000714 WO2007124578A1 (en) 2006-04-27 2007-04-27 Assessment and reduction of risk of graft-versus-host disease

Publications (1)

Publication Number Publication Date
ATE539170T1 true ATE539170T1 (de) 2012-01-15

Family

ID=38655008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07719640T ATE539170T1 (de) 2006-04-27 2007-04-27 Abschätzung und verringerung des risikos von graft-versus-host-reaktion

Country Status (6)

Country Link
US (4) US7763425B2 (de)
EP (1) EP2021534B1 (de)
JP (1) JP5171812B2 (de)
AT (1) ATE539170T1 (de)
CA (1) CA2650507A1 (de)
WO (1) WO2007124578A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957704A1 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2604703B1 (de) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Verfahren zur Bewertung der Haltbarkeit eines Pfropfs im Körper eines Empfängers fester Organtransplantate
WO2009075811A1 (en) * 2007-12-07 2009-06-18 Tufts Medical Center, Inc. Compositions and methods for immortalizing cells and screening for anti-cancer agents
CN101960022A (zh) * 2008-01-22 2011-01-26 维里德克斯有限责任公司 Ⅱ期和ⅲ期结肠癌的分子分期和预后
US20110201519A1 (en) * 2008-08-18 2011-08-18 Sarwal Minnie M Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject
US9938579B2 (en) 2009-01-15 2018-04-10 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
WO2010096160A1 (en) * 2009-02-17 2010-08-26 The Board Of Trustees Of The Leland Stanford Junior University Compartment-specific non-hla targets for diagnosis and prediction of graft outcome
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
CA2794255C (en) 2010-03-25 2020-01-14 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
US20120277999A1 (en) * 2010-10-29 2012-11-01 Pbd Biodiagnostics, Llc Methods, kits and arrays for screening for, predicting and identifying donors for hematopoietic cell transplantation, and predicting risk of hematopoietic cell transplant (hct) to induce graft vs. host disease (gvhd)
EP2650367A4 (de) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd Menschlicher monoklonaler antikörper
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201021149D0 (en) * 2010-12-14 2011-01-26 Georg August Uni Gottingen Stiftung Offentlichen Rechts Use of a skin explant assay for mRNA expression analysis for the identification of new genes and drug targets associated with graft versus host disease
WO2012139051A2 (en) 2011-04-06 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for iga nephropathy
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
JP5904801B2 (ja) * 2012-01-17 2016-04-20 シスメックス株式会社 制御性t細胞への分化誘導能の予測方法及びその方法に用いられるバイオマーカー、並びにそれらの利用
US20150275301A1 (en) * 2012-10-05 2015-10-01 Hitachi Chemical Co., Ltd. URINE EXOSOME mRNAS AND METHODS OF USING SAME TO DETECT DIABETIC NEPHROPATHY
WO2014182330A1 (en) 2013-05-06 2014-11-13 Hitachi Chemical Company Ltd Devices and methods for capturing target molecules
WO2014189635A1 (en) * 2013-05-20 2014-11-27 The Trustees Of Columbia University In The City Of New York Tracking donor-reactive tcr as a biomarker in transplantation
WO2015169597A1 (en) 2014-05-07 2015-11-12 Cytolon Ag Methods and systems for predicting alloreactivity in transplantation
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
WO2016077537A1 (en) 2014-11-12 2016-05-19 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US9563744B1 (en) * 2014-12-03 2017-02-07 Biodesix, Inc. Method of predicting development and severity of graft-versus-host disease
CN104878099B (zh) * 2015-05-15 2018-02-16 西北农林科技大学 山羊atbf1基因单核苷酸多态性的检测方法及其应用
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
US11713487B2 (en) 2017-07-14 2023-08-01 The Regents Of The University Of California Methods of predicting transplant rejection risk
EP3919917B1 (de) * 2019-01-30 2025-09-17 Craif Inc. Vorrichtung und verfahren zur rückgewinnung von biomolekülen sowie vorrichtung und verfahren zur analyse von biomolekülen
KR20220012266A (ko) * 2019-05-23 2022-02-03 스페이스크래프트 세븐, 엘엘씨 영아 악성 골화석증을 위한 유전자 요법 벡터
JP2025512574A (ja) * 2022-04-22 2025-04-17 スペースクラフト セブン リミテッド ライアビリティ カンパニー AAVベクターを使用するB細胞リンパ腫2関連Anthanogene 3 (BAG3)遺伝子治療
WO2024151826A1 (en) * 2023-01-12 2024-07-18 Jasper Therapeutics, Inc. Methods for the prevention and treatment of gvhd
WO2025259362A1 (en) * 2024-06-12 2025-12-18 The Board Of Trustees Of The Leland Stanford Junior University Enhancements for proximal signaling car activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426540A1 (en) * 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP2005536212A (ja) * 2002-08-22 2005-12-02 ノバルティス アクチエンゲゼルシャフト 慢性拒絶反応の診断法
JP4316617B2 (ja) * 2003-12-03 2009-08-19 ノバルティス アクチエンゲゼルシャフト 移植片拒絶反応のバイオマーカー
WO2005074540A2 (en) 2004-01-30 2005-08-18 University Of Pennsylvania Novel predictors of transplant rejection determined by peripheral blood gene-expression profiling

Also Published As

Publication number Publication date
JP2009538599A (ja) 2009-11-12
US20100248254A1 (en) 2010-09-30
EP2021534A4 (de) 2009-11-11
US20070264272A1 (en) 2007-11-15
CA2650507A1 (en) 2007-11-08
US20130324427A1 (en) 2013-12-05
US9102981B2 (en) 2015-08-11
US7763425B2 (en) 2010-07-27
EP2021534B1 (de) 2011-12-28
EP2021534A1 (de) 2009-02-11
US20150337374A1 (en) 2015-11-26
JP5171812B2 (ja) 2013-03-27
WO2007124578A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
EP2021534A4 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
ATE517992T1 (de) Funktionelle und hyperfunktionelle sirna
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
DK1737974T3 (da) Fremgangsmåder til identifikation af proteiner med stivelsesphosphorylerende enzymatisk aktivitet
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
DE602007002568D1 (de) Chloramphenicolresistenz-selektion bei bacillus licheniformis
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2007047408A3 (en) Promac signature application
DE602007000894D1 (de) Verstärkte Reaktivierung wärmebeständiger, reversibel inaktivierter Enzyme
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
WO2005065365A3 (en) Systems and methods for aesthetic improvement
ATE452149T1 (de) Modifizierte polyolefinwachse
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
EA200702193A1 (ru) Гликозилирование белков
ITMO20030081A0 (it) Bioreattore,particolarmente per organi bioartificiali.
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)